AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17143194
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aliskiren (300 mg) and HCTZ (25 mg)
Trial: 17143194
Drug: HCTZ monotherapy
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCTZ monotherapy (6.25, 12.5 or 25 mg)
Trial: 11841195
Drug: Flunisolide 500
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flunisolide 500 microg administered twice daily by nebulizer for 4 weeks
Trial: 11841195
Drug: Budesonide 500
RxNorm normalized name: Budesonide 500 microgram/mL solution for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 500 microg administered twice daily by nebulizer for 4 weeks
Trial: 8001599
Drug: New acenocoumarol
RxNorm normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New acenocoumarol tablet formulation (12 mg single oral dose)
Trial: 8001599
Drug: New acenocoumarol
RxNorm normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New acenocoumarol tablet formulation
Trial: 3892994
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin (Heparin Leo 5000 I.U. subcutaneously twice daily)
Trial: 29678962
Drug: Letter from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letter from GP outlining importance of asthma medication (delivered in late July)
Trial: 1319601
Drug: Oral THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral THC
Trial: 8712322
Drug: Metoclopramide 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 0.25 mg.kg‐1
Trial: 3888766
Drug: Intramuscular ceruletide
RxNorm normalized name: ceruletide diethylamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ceruletide
Trial: 27435894
Drug: Adenosine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (4 to 512 μg)
Trial: 19067728
Drug: Pegvisomant (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegvisomant (20 mg daily for 14 days)
Trial: 14969833
Drug: Lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg/d administered preoperatively in HBV active replication group (15 recipients)
Trial: 14969833
Drug: Lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg/d administered preoperatively in HBV inactive replication group (7 recipients)
Trial: 9072566
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave lithotripsy (ESWL) monotherapy
Trial: 8134206
Drug: Indomethacin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.1 mg/kg intravenously at 6 to 12 postnatal hours and every 24 hours for two more doses)
Trial: 3310942
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg four times a day (short-term phase)
Trial: 3310942
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg at bedtime (maintenance phase)
Trial: 29288590
Drug: Ampcare Effective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampcare Effective Swallowing Protocol (ESP), treatment 5 days/week for 4 weeks.
Trial: 29288590
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (speech and language therapy dysphagia care).
Trial: 22623396
Drug: D2 at
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 at 5 μg/d
Trial: 22623396
Drug: D2 at
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 at 10 μg/d
Trial: 22623396
Drug: D3 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D3 at 5 μg/d
Trial: 22623396
Drug: D3 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D3 at 10 μg/d
Trial: 12088961
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% with epinephrine 5 microg/mL
Trial: 2196522
Drug: Standard methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard methylphenidate (twice a day)
Trial: 2196522
Drug: Sustained-release methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release methylphenidate (SR-20 Ritalin)
Trial: 2196522
Drug: Sustained-release dextroamphetamine
RxNorm normalized name: dextroamphetamine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release dextroamphetamine (Dexedrine Spansule)
Trial: 19810365
Drug: All four
RxNorm normalized name: Jackson's The Original All Fours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All four medications
Trial: 16970947
Drug: Moderate statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate statin treatment
Trial: 11730209
Drug: PG synthesis
RxNorm normalized name: PG
DrugBank: 1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) (DB11331)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PG synthesis inhibitor (PGSI)
Trial: 8229035
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (500 mg for five consecutive days)
Trial: 8229035
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone (500 mg for five consecutive days)
Trial: 26206095
Drug: 750 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 μg vitamin D3
Trial: 26206095
Drug: 1500 μg
RxNorm normalized name: flunixin
DrugBank: Flunixin (DB11518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 μg vitamin D3
Trial: 23642949
Drug: Caralluma fimbriata
RxNorm normalized name: CARALLUMA FIMBRIATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caralluma fimbriata extract (500 mg capsules twice daily)
Trial: 23642949
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mg capsules twice daily)
Trial: 17252909
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of pulsed low frequency magnetic field (PLFMF) with kinesitherapy
Trial: 17252909
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of pulsed low frequency magnetic field (PLFMF) with kinesitherapy
Trial: 9055905
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment at daily doses of 0.1, 0.2, or 0.3 IU/kg (0.033, 0.067, or 0.1 mg/kg) s.c.
Trial: 1390340
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily oral ondansetron
Trial: 1390340
Drug: Three times
RxNorm normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times daily oral ondansetron
Trial: 3493519
Drug: Beta-lactamase-susceptible agents
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-lactamase-susceptible agents
Trial: 25958941
Drug: 0.7g CHO.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7g CHO.kg(‐1) supplement
Trial: 25958941
Drug: 0.35g CHO.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.35g CHO.kg(‐1) supplement
Trial: 23663752
Drug: Apremilast 20
RxNorm normalized name: apremilast 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast 20 mg BID
Trial: 23030767
Drug: Apremilast 20
RxNorm normalized name: apremilast 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast 20 mg QD
Trial: 18293379
Drug: Intensive myeloablative
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive myeloablative chemotherapy and autologous hematopoietic progenitor cell rescue (AuHCR)
Trial: 10717717
Drug: Methylprednisolone 240
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 240 mg daily for 3 days (group B)
Trial: 10717717
Drug: Methylprednisolone 40
RxNorm normalized name: methylprednisolone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 40 mg daily for 3 days (group C)
Trial: 1312317
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (18 Max-EPA capsules daily, 3.24 g eicosapentaenoic acid, 2.16 g docosahexaenoic acid)
Trial: 2997764
Drug: Microcrystalline hydroxyapatite
RxNorm normalized name: Microcrystalline Hydroxyapatite Concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline hydroxyapatite compound (MCHC)
Trial: 28382392
Drug: Silicon nitride
RxNorm normalized name: Silicon nitride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicon nitride implants
Trial: 25456166
Drug: Daily 0.1-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 0.1-mg subcutaneous GnRHa until day of beta-HCG (n = 224)
Trial: 25456166
Drug: Daily vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vaginal progesterone suppositories (both groups)
Trial: 25456166
Drug: Stopped GnRHa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stopped GnRHa on day of HCG injection (n = 222)
Trial: 23574148
Drug: Pre-emptive antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-emptive antifungal treatment
Trial: 23574148
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antifungal treatment)
Trial: 20097587
Drug: Cetirizine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 0.4 mg/kg orally twice daily for 3 weeks
Trial: 18007138
Drug: Oral hypoglycaemics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hypoglycaemics like metformin
Trial: 11917051
Drug: Candesartan 8
RxNorm normalized name: candesartan 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 8 mg added to ACEI regimen
Trial: 30946525
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg extended-release tolterodine at bedtime
Trial: 25960284
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (andrographolide sulfonate plus conventional therapy)
Trial: 11701070
Drug: Megadose steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Megadose steroid therapy (group S)
Trial: 11701070
Drug: Lipoprostaglandin E(1)
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lipoprostaglandin E(1) therapy (group L)
Trial: 9337183
Drug: KCl infusion
RxNorm normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KCl infusion (maximum, 40 mEq) in healthy subjects treated with quinidine sulfate
Trial: 9337183
Drug: KCl infusion
RxNorm normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KCl infusion (maximum, 40 mEq) in CHF patients
Trial: 7887823
Drug: Filling the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filling the dialysis circuit with 6.7% human albumin in saline for 10 min at a flow rate of 100 ml/min before HD
Trial: 3126634
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (NTG) 10 mg
Trial: 3126634
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (NTG) 5 mg
Trial: 30217412
Drug: Oncology rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oncology rehabilitation with motivational interviewing delivered once weekly for 7 weeks via telephone by a physiotherapist
Trial: 26187456
Drug: Dronabinol 30
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dronabinol 30 mg/d
Trial: 23725999
Drug: Everolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (10 mg/d) with concurrent radiation (60 Gy in 30 fractions) and temozolomide (75 mg/m2 per day)
Trial: 20979460
Drug: Acupressure (eight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupressure (eight treatments over 4 weeks)
Trial: 16957130
Drug: Patients on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients on dopamine agonists
Trial: 16957130
Drug: Patients not
RxNorm normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients not specified as on dopamine agonists
Trial: 12562338
Drug: Wax epilation
RxNorm normalized name: Candelilla Wax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wax epilation followed by long-pulsed alexandrite laser treatment
Trial: 7880221
Drug: Active medications
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active medications and surgery
Trial: 23835718
Drug: Obinutuzumab (GA101)
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab (GA101) 1,600/800 mg
Trial: 23835718
Drug: Obinutuzumab (GA101)
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab (GA101) 400/400 mg
Trial: 16958565
Drug: Risperidone (0.25-4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (0.25-4.5 mg/day, mean dose 1.62 ± 1.02 mg/day)
Trial: 16958565
Drug: Olanzapine (2.5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (2.5-20 mg/day, mean dose 8.18 ± 4.41 mg/day)
Trial: 16958565
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Risperidone and Olanzapine)
Trial: 15041031
Drug: Fatty acid
RxNorm normalized name: FATTY ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fatty acid treatment
Trial: 1791060
Drug: Placebo (lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose capsule)
Trial: 1645825
Drug: Mixed bacterial
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed bacterial vaccine (MBV) in Series 1
Trial: 1645825
Drug: Mixed bacterial
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed bacterial vaccine (MBV) in Series 2
Trial: 1645825
Drug: Mixed bacterial
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed bacterial vaccine (MBV)
Trial: 28367037
Drug: Topical sodium
RxNorm normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sodium diclofenac 0.1%
Trial: 24099839
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (200mg immediately after each chemotherapy infusion)
Trial: 24099839
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous fumarate (200mg three times a day)
Trial: 21341889
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) for PTSD and depressive symptoms
Trial: 9727727
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg plus Pindolol 7.5 mg
Trial: 9727727
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg plus Placebo
Trial: 9836512
Drug: Insulin 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin 0.25 mU x kg(‐1) x min(‐1)
Trial: 9836512
Drug: Insulin 0.5
RxNorm normalized name: Monoject Insulin 0.5mL U-100 Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin 0.5 mU x kg(‐1) x min(‐1)
Trial: 9836512
Drug: Insulin 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin 1.0 mU x kg(‐1) x min(‐1)
Trial: 9836512
Drug: Insulin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (all dosages)
Trial: 2501714
Drug: Ferric chondroitin
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric chondroitin sulfate (90 mg of iron)
Trial: 2501714
Drug: Ferritin iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferritin iron (91 mg)
Trial: 23941549
Drug: Dexmedetomidine (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.6 μg/kg/h continuous infusion)
Trial: 23941549
Drug: Saline (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.9% sodium chloride for injection, maintenance infusion)
Trial: 19396417
Drug: Long-term psychoanalysis
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term psychoanalysis (defined as fewer than 50 treatment sessions)
Trial: 15329210
Drug: Pegasys (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegasys (180 microg injection once a week for 24 weeks)
Trial: 15329210
Drug: Roferon-A (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roferon-A (3 MU injection three times a week for 24 weeks)
Trial: 11367659
Drug: Integrated traditional
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated traditional Chinese and Western medicine (TCM‐WM)
Trial: 3535552
Drug: Triple dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple dose cefoxitin
Trial: 29955115
Drug: Risperidone treatment
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone treatment in ASD patients
Trial: 25085771
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (positive control)
Trial: 25085771
Drug: Targeted selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted selective treatment (TST)
Trial: 11472451
Drug: Repaglinide, 1‐4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide, 1‐4 mg at mealtimes
Trial: 11472451
Drug: Glipizide, 5‐15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide, 5‐15 mg daily
Trial: 6451461
Drug: DS 103-282
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS 103-282 (5 mg, three times daily for 7 days)
Trial: 6451461
Drug: Diazepam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (5 mg, three times daily for 7 days)
Trial: 27908227
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (10,000 IU soft gels administered three times per week)
Trial: 27908227
Drug: Placebo (vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vitamin A soft gels devoid of active ingredients administered thrice weekly)
Trial: 17479946
Drug: SQV-RTV-ATV regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQV-RTV-ATV regimen (1500 mg saquinavir, 100 mg ritonavir, 300 mg atazanavir once per day without NRTIs)
Trial: 17479946
Drug: SQV formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQV formulations (200 mg vs. 500 mg)
Trial: 12365904
Drug: Laser trabeculoplasty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser trabeculoplasty plus topical betaxolol hydrochloride (n = 129)
Trial: 12365904
Drug: No initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No initial treatment (n = 126)
Trial: 12365904
Drug: Laser trabeculoplasty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser trabeculoplasty plus topical betaxolol hydrochloride
Trial: 2726279
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg + 20 mg codeine
Trial: 820357
Drug: Synthetic thyrotrophin
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic thyrotrophin releasing factor (TRF, Ro 08‐6270) administered via rapid i.v. injection
Trial: 30591415
Drug: Alirocumab dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab dose increase (from 75 to 150 mg Q2W)
Trial: 26131612
Drug: Liuzijue Qigong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liuzijue Qigong (LQG) program consisting of four 45‐minute sessions each week and daily walking for 30 minutes for 6 months
Trial: 26131612
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group walking daily for 30 minutes